Clinical Trials Directory

Trials / Unknown

UnknownNCT05442372

Prevalence of HBV in Pregnancy

Prevalence of Hepatitis B Virus Infection in Pregnancy

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
Female
Age
16 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The most common mode of HBV transmission is materno-fetal transmission mainly during labor. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women.

Detailed description

Hepatitis B virus (HBV) is a cause of a vaccine-preventable life-threatening infection of the liver. Worldwide, the estimated number of cases of chronic HBV infection is 296 million cases with about 820 000 deaths, mostly due to liver cirrhosis and hepatocellular carcinoma. The prevalence of HBV infection among pregnant women is estimated to be 1.5-9.5%. The most important risk factor of materno-fetal transmission is high viremia. Other factors include hepatitis B e antigen (HBeAg) seropositivity, HBV S variant, and threatened preterm labor. Quantitative hepatitis B surface antigen (HBsAg) was postulated as a surrogate marker for HBV high viremia in pregnant women by many authors. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women.

Conditions

Timeline

Start date
2022-06-15
Primary completion
2023-02-15
Completion
2023-04-15
First posted
2022-07-05
Last updated
2022-12-23

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05442372. Inclusion in this directory is not an endorsement.